Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06627751
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
Mezigdomide Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase II Clinical Trial of MezigdomideCarfilzomibDexamethasone MeziKD in Patients With Relapsed or Refractory Multiple Myeloma MM With Extramedullary Disease EMD
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial studies how well mezigdomidecarfilzomibdexamethasone MeziKD works in treating patients with multiple myeloma MM that has come back after a period of improvement relapsed or that does not respond to treatment refractory and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body extramedullary disease EMD Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system including activation of T-lymphocytes and downregulation of the activity of other proteins some of which play key roles in the proliferation of certain cancer cell types Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth Dexamethasone is a type of corticosteroid and is used to kill myeloma cells It is used with other drugs to treat multiple myeloma Giving MeziKD may kill more cancer cells in patients with relapsedrefractory multiple myeloma RRMM with EMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None